Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Abingdon Health Plc (LSE:ABDX): Why This London-Listed Stock Is Drawing Investor Attention on 23 October 2026

Investors are looking for verifiable operating milestones, funding visibility and evidence of execution.

Ankur Sharma | 23 October 2026

AOTI, Inc. (LSE:AOTI): Why This London-Listed Stock Is Drawing Investor Attention on 23 October 2026

Investors are looking for verifiable operating milestones, funding visibility and evidence of execution.

Ankur Sharma | 23 October 2026

Avacta Group PLC (LSE:AVCT) in Focus: The Healthcare Story Investors Are Watching on 23 October 2026

• Avacta Group PLC operates in oncology drug development and diagnostics technology, placing company-specific execution at the centre of its investment case.

Ankur Sharma | 23 October 2026

Croda’s Recovery Watch: When Will Specialty Ingredients Demand Improve? (LSE:CRDA)

On 23 October 2026, Croda International plc (LSE:CRDA) can be assessed against a cautious UK market backdrop. London equities are responding to firmer oil prices, geopolitical uncertainty and weaker sentiment following losses in global technology shares. The FTSE 100 has shown sensitivity to energy-heavy …

Ankur Sharma | 23 October 2026

Avacta’s Pre|CISION Data Raises the Stakes for Its Clinical Development Story

Avacta Group (AIM:AVCT) is in focus on 23 October 2026 following the reported development. Avacta’s latest Pre|CISION platform data has brought the company’s scientific rationale and development pathway into focus. For a biotechnology business, platform-level findings can support the case for further research, but …

Ankur Sharma | 23 October 2026

Avacta (LSE:AVCT): Could New Cancer Data Put Its Targeted Drug Platform Back in the Spotlight?

Avacta is in focus after highlighting new preclinical findings for AVA6103 and outlining the FOCUS-01 Phase 1 clinical-trial design. The company is developing targeted oncology medicines using its pre|CISION controlled-release peptide-drug conjugate platform. The latest data describe tumour response in a patient-derived model of …

Ankur Sharma | 23 October 2026

AstraZeneca’s Ultomiris US Approval for IgAN: The Commercial Opportunity to Watch

AstraZeneca is in focus after the reported US approval of Ultomiris for IgA nephropathy (IgAN). The decision could broaden the medicine’s addressable market, but the revenue opportunity depends on the approved label, eligible patients, uptake, reimbursement and the competitive treatment landscape.

Ankur Sharma | 23 October 2026

Verici Dx and the US Kidney Care Plan: What Could It Mean for Diagnostic Adoption?

Verici Dx is in focus following developments around a US Kidney Care National Plan. The potential relevance lies in whether policy and care pathways create stronger demand for diagnostics that help clinicians assess kidney disease and transplant outcomes. Participation and commercial benefit should not …

Ankur Sharma | 23 October 2026

Renalytix’s US Kidney Care Plan Opportunity: Can Policy Translate Into Paid Testing?

Renalytix is in focus as investors assess whether the US kidney-care policy environment could support wider adoption of kidney disease diagnostics. The key issue is not simply whether a national initiative recognises a clinical need, but whether it changes testing pathways, reimbursement and purchasing …

Ankur Sharma | 23 October 2026

CVS Group Annual Report: Debt, Vet Demand and Investment Priorities in Focus

CVS Group is in focus following publication of its annual report and AGM notice. Investors will be looking beyond headline revenue to the quality of earnings, leverage, investment needs and evidence that veterinary practices can sustain demand while managing staffing and cost pressures.

Ankur Sharma | 23 October 2026
Support

Hi! How can we help you today?

Loading…